Callitas Health (Callitas Health) Total Equity : $-4.44 Mil (As of Sep. 2020)

View and export this data going back to 2008. Start your Free Trial

What is Callitas Health Total Equity?

Callitas Health's total equity for the quarter that ended in Sep. 2020 was $-4.44 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Callitas Health Total Equity Historical Data

The historical data trend for Callitas Health's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Callitas Health Total Equity Chart

Callitas Health Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Total Equity

Get a 7-Day Free Trial

-0.81

0.16

-0.10

-3.86

-4.03

Callitas Health Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Total Equity	Get a 7-Day Free Trial															-	-4.03	-4.19	-4.28	-4.44

Callitas Health Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Callitas Health's Total Equity for the fiscal year that ended in Dec. 2019 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2019 )	-	Total Liabilities(Q: Dec. 2019 )
	=	0.14	-	4.174
	=	-4.03

Callitas Health's Total Equity for the quarter that ended in Sep. 2020 is calculated as

Total Equity	=	Total Assets(Q: Sep. 2020 )	-	Total Liabilities(Q: Sep. 2020 )
	=	0.103	-	4.537
	=	-4.43

Callitas Health Total Equity Related Terms

Thank you for viewing the detailed overview of Callitas Health's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Callitas Health (Callitas Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Callitas Health Inc (OTCPK:MPHMF) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

734 - 1055 Dunsmuir Street, Vancouver, BC, CAN, V7X 1B1

Website

http://www.callitas.com

Callitas Health Inc is a clinical-stage company. It is engaged in developing technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications. The company's products offering includes ToConceive, C-103 Reformulated Orlistat, and Extrinsa. ToConceive is a fertility enhancing moisturizer. It is clinically proven to increase a woman's own natural conception lubrication, called transudate, to aid in conception. Orlistat is FDA-approved for weight management and sold by Roche as Xenical (prescription) and by GlaxoSmithKline as alli. Extrinsa focuses on women with orgasm and arousal difficulties. The topical, local, and the non-systemic product is also non-hormonal and does not affect the central nervous system.